drugset / Trial / NCT02204917

CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children

NCT02204917

Phase 1/2 Completed 31 enrolled Kassa Darge
NaSingle-groupOpen-labelDiagnostic

Summary

In this clinical trial the investigators aim to evaluate the diagnostic feasibility and safety of ceVUS with the intravesical use of OPTISON for vesicoureteral reflux detection and urethral imaging in children.

Timeline

Start
2014-07
Primary completion
2016-03
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Optison Diagnostic / imaging agent 0.1 %
Subject Optison Diagnostic / imaging agent 0.3 ml
Subject Optison Diagnostic / imaging agent 0.5 %
Subject Optison Diagnostic / imaging agent 3 ml

Indications